1. Overview
  2. All Stocks
  3. Structure Therapeutics Inc. American Depositary Shares

Structure Therapeutics (GPCR.US) Stock Rating 2026/2027: Strong Buy – Stock Analysis

0.00
Analysis framework by , founder of TradeDesk · Data: EODHD, insider trades from SEC Form 4 filings · Updated
Share this analysis:

No analysts currently cover Structure Therapeutics with a public price target. We add the price target automatically as soon as at least one analyst publishes a rating. Until then, use the technical analysis and the key figures below.

Analyst Ratings for Structure Therapeutics stock in 2026: Strong Buy

16 analysts cover Structure Therapeutics. There is broad agreement on a positive view — 93.8% recommend buying.

Consensus: Strong Buy (4.63/5)
Strong Buy
11 (68.8%)
Buy
4 (25%)
Hold
1 (6.3%)
Strong Sell Sell Hold Buy Strong Buy
4.63 out of 5 based on 16 analysts
↑ Back to navigation

About Structure Therapeutics – Biotechnology

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Read more about the company

Key Figures for Structure Therapeutics

$1.5B Market cap
- Revenue
Biotechnology Industry
- P/E
- P/S
1.99 P/B
United States Listed on exchange
structuretx.com Website
Healthcare Sector

What kind of stock is Structure Therapeutics?

Speculative stock

Structure Therapeutics is classified as a speculative stock.

Score Overview for Structure Therapeutics

💰 Value Score 16/100 (Very Low)
⭐ Quality Score 13/100 (Very Low)
🚀 Momentum Score 3/100 (Very Low)
📊 Total Score 10/100

⚠️ 3 red flags identified 2 critical

Our analysis has identified 3 potential risk factors in Structure Therapeutics that investors should be aware of.

🚨 Weak financial health: The Piotroski score is only 1/9 – the company shows signs of weakened profitability, liquidity or capital structure.
🚨 Negative return on equity: ROE is -20.2% – the company is generating a negative return for shareholders.
⚠️ High short interest: 14.5% of the shares are sold short – many professional investors are betting on price declines.

📈 Valuation

The P/B ratio is 2.0.

🏦 Financial Health

The Piotroski score is 1 out of 9 — weak financial health, be careful. Altman Z2 is 23.53 (healthy balance sheet — low risk). The debt-to-equity ratio (D/E) is 4.5% — low debt, a solid balance sheet.

🚀 Momentum & Short Interest

Short interest is 14.48% — very high, the market is skeptical.

↑ Back to navigation

Structure Therapeutics Short Selling 2026: 14.5% Sold Short

Very high short interest: 14.5% of the free float
Short % of free float
14.5%
Assessment
Very high short interest
Short squeeze risk
High
Data source
EODHD
Reported about twice a month
The stock has a very high share of short selling. Between 10-20% of the freely traded shares are sold short, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains.

What does this mean for you as an investor?
A short interest of 14.5% means that 14.5% of the freely traded shares in Structure Therapeutics have been borrowed and sold by investors betting on falling prices. On positive surprises (e.g. a strong earnings report), short sellers can be forced to buy back shares quickly to close their positions, which can cause a short squeeze with sharp price gains in a short time.

The next potential catalyst is the earnings report on Nov 5, 2026. With a short interest of 14.5%, the report can trigger considerable volatility.

Short interest comes from our data provider EODHD. The figure is reported about twice a month; we check it every trading day.
Short Interest Scale
0% 2% 5% 10% 20%+
Low Moderate High Very High Extreme
▲
14.5%

↑ Back to navigation

When Does Structure Therapeutics Report Earnings – Next Date: Nov 5, 2026

The next earnings report from Structure Therapeutics is scheduled for November 5, 2026, after the market closes. This report covers the third quarter (Q3), which ended on September 30, 2026.



↑ Back to navigation

Technical Analysis of Structure Therapeutics 2026 – Signal: Sell

Overall Technical Signal: Sell

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated October 26, 2026.

Trend Analysis of Structure Therapeutics Inc. American Depositary Shares

Structure Therapeutics Inc. American Depositary Shares is in a short-term downtrend. The price of $21.19 is 16.9% below the 20-day average ($25.50). Medium term, the picture is negative: the price is 42.1% below the 50-day average ($36.61). Long term, the stock is 57.9% below the 200-day average ($50.36), which signals a long-term downtrend.

Death Cross: The 50-day average (36.61) is below the 200-day average (50.36), which is a classic bearish signal for Structure Therapeutics Inc. American Depositary Shares.

Is Structure Therapeutics Inc. American Depositary Shares overbought or oversold?

Structure Therapeutics Inc. American Depositary Shares has an RSI of 20.4, which places the stock in oversold territory (below 30). The trend is neutral, so the oversold level should be interpreted with caution. Wait for confirmation from MACD or a trend reversal.

MACD Analysis for Structure Therapeutics Inc. American Depositary Shares

Daily MACD: MACD is negative (-4.321), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is above the signal line (-4.633) by 0.312, which suggests the negative momentum is fading – a potential trend reversal could be ahead.

Weekly MACD: MACD5 is negative (-6.033), which indicates a broader bearish long-term trend. MACD5 is below the signal line (-2.883) by 3.150, which confirms continued negative long-term momentum.

Overall MACD assessment: Both the daily and weekly trend are bearish (MACD negative). However, momentum shows signs of improving on a daily basis – a potential trend reversal could be ahead, but it is not confirmed yet.

Risk Profile for Structure Therapeutics Inc. American Depositary Shares

Structure Therapeutics Inc. American Depositary Shares has an annual standard deviation of 119.4%, which classifies the stock as Extremely speculative. Only risk-tolerant investors should consider this stock, because the price swings can be very large.

Overall Technical Conclusion for Structure Therapeutics Inc. American Depositary Shares

Trend: Neutral/mixed.

MACD trend (zero line): Daily bearish (-4.321). Weekly bearish (-6.033).

MACD momentum (signal): Daily rising. Weekly falling.

RSI: 20.4 – oversold.

Technical signal: Sell

The trend is negative and MACD is below the zero line, which confirms the bearish momentum. Consider reducing the position or setting a stop-loss.

↑ Back to navigation

Frequently Asked Questions About Structure Therapeutics stock in 2026

Should you buy Structure Therapeutics stock now?
No, the technical signal for Structure Therapeutics is currently Sell. Structure Therapeutics trades at $0.00 as of Oct 26, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -4.321 with rising momentum (signal: -4.633); RSI is at 20.4 (oversold), which could point to a potential buying opportunity. This is a technical observation based on current data, not investment advice.
What is the price target for Structure Therapeutics stock?
There is currently no active analyst price target for Structure Therapeutics.
Is Structure Therapeutics a dividend stock?
No, Structure Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Structure Therapeutics stock?
Structure Therapeutics is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 119.4%, which classifies the stock as Extremely speculative. In addition, an RSI of 20.4 signals oversold (potential bottom).
Is Structure Therapeutics overvalued?
Structure Therapeutics has the following valuation ratios: a P/B ratio of 2.0.
Is Structure Therapeutics overbought?
No, Structure Therapeutics is actually oversold with an RSI of 20.4 (below 30). The technical indicators show: RSI is at 20.4 (below the 30 mark), which actually signals the price is oversold – the opposite of overbought. In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Structure Therapeutics earnings report?
Structure Therapeutics reports its next earnings on November 5, 2026. The stock currently trades at $0.00. The RSI is at 20.4, so the report can reinforce the current technical trend.
Is Structure Therapeutics shorted?
Yes, Structure Therapeutics is shorted with 14.5% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Structure Therapeutics stock?
There is currently no registered insider trading for Structure Therapeutics.
Is Structure Therapeutics a good stock?
Based on our total score, Structure Therapeutics is rated as a disastrous stock with a total score of 10 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 16/100, Quality: 13/100, Momentum: 3/100. Whether now is the time to buy is a separate question: the technical signal is Sell. Whether Structure Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Structure Therapeutics stock?
The outlook for Structure Therapeutics based on current data: the next earnings report is due on Nov 5, 2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Structure Therapeutics stock moving?
Structure Therapeutics is moving right now. The technical indicators show: short interest is 14.5% (high – many are betting on a decline). For the latest context, see our technical analysis and insider section above.
How high can Structure Therapeutics go?
There is currently no active analyst price target for Structure Therapeutics. The stock has traded between $20.73 and $94.90 over the last 52 weeks. The price is 100.0% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Structure Therapeutics fall?
We lack enough history to give a specific floor for Structure Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Structure Therapeutics do?
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and bi... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Structure Therapeutics as an investment.
Did Structure Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Structure Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Structure Therapeutics making money or losing money?
We have no current profitability data for Structure Therapeutics. See the latest report in the earnings history above.
Can Structure Therapeutics go bankrupt?
The bankruptcy risk of Structure Therapeutics is rated as low. Altman Z2 (a model for assessing financial distress) is 23.53 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 4% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Structure Therapeutics have a lot of debt?
No, Structure Therapeutics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 4%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
↑ Back to navigation

Other Stocks in Healthcare

Compare Structure Therapeutics with other stocks in the healthcare sector. Click a stock to see its technical analysis, insider trading and key figures.

See all 115 stocks in the Healthcare sector

Explore More